PhaseBio Pharmaceuticals, Inc.

NASDAQ (USD): PhaseBio Pharmaceuticals, Inc. (PHAS)

Last Price

0.07

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Overview

Market Cap

0

Shares Outstanding

0

Avg Volume

1,785,986

Avg Price (50 Days)

0.43

Avg Price (200 Days)

0.91

PE Ratio

-0.03

EPS

-2.38

Earnings Announcement

Previous Close

0.07

Open

0.08

Day's Range

0.0665 - 0.092

Year Range

0.041 - 4.08

Trading Volume

8,603,716

Price Change Highlight

1 Day Change

0.00%

5 Day Change

0.00%

1 Month Change

0.00%

3 Month Change

-22.11%

6 Month Change

-94.11%

Ytd Change

84.47%

1 Year Change

-95.26%

3 Year Change

-98.65%

5 Year Change

-98.60%

10 Year Change

-98.60%

Max Change

-98.60%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment